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Abstract
Peptidomimetic research is an approach to identify peptide-based drugs designed to mimic structural,
conformational, and biological properties of peptides while overcoming their limitations, such as
protease instability and poor cell penetration. With recent advances in ribosomal synthesis of
peptides containing unnatural amino acids, this technology appears suitable for preparing large
structurally diverse libraries of peptidomimetics for drug discovery screening.
Introduction and context
Biologically active peptides are attracting increasing
interest as potential therapeutic agents or leads toward
such agents [1]. For many applications, native peptides
are not ideal due to inherent issues, including short
biological half-life (rapid cleavage by proteases and/or
fast clearance), poor membrane permeability that limits
bioavailability and access to intracellular targets, and
physical-chemical properties [2]. Research over the last
several decades has focused on the discovery, design, and
synthesis of novel structures that possess the desirable
properties of native peptides while overcoming their
liabilities [3,4]. These ‘peptidomimetics’ have originated
from both chemical synthesis and natural product
sources [5,6]. An emerging complementary technology
providing access to amide backbone-based peptidomi-
metic structures is ribosomal synthesis using unnatural
amino acids. The attractive potential of ribosomal
synthesis is rapid and specific preparation of large
structurally diverse libraries of peptidomimetics for
screening against biological targets.
The history of this approach and key recent advances in
the technology have been detailed in review articles [7,8]
in the last year and will be treated only briefly. Twenty
years ago, two groups were able to reassign stop (or
nonsense) codons to non-proteinogenic amino acids,
and using chemically generated misaminoacylated
transfer ribonucleic acid (tRNA), they demonstrated the
incorporation of unnatural amino acids into a protein
and a polypeptide [9,10]. This ‘nonsense suppression’ is
suitable for the incorporation of only a single type of
non-proteinogenic amino acid into a peptide chain. A
complementary method using nucleotide four-base
codons allowed the incorporation of two or three
unnatural amino acids but is still limited in its generality.
Other limitations of these methods are the restricted
choice of unnatural amino acids that can be incorporated
and the technically challenging process of chemically or
enzymatically aminoacylating tRNA.
One key technical advance in the current decade was the
development of a reconstituted Escherichia coli cell-free
translation system (for example, protein synthesis using
recombinant elements, or PURE [11]) in which certain
amino acids and aminoacyl-tRNA synthetases (aaRSs)
are removed from the translation elements. Specific
vacant codons thus can be created and used for unnatural
amino acids of choice. Lack of competition from the
natural aminoacyl-tRNA thereby improves the efficiency
of sense suppression, and the potential of this approach
for production of large screenable libraries of small
peptidomimetics was proposed [12]. It was emphasized
that such directed in vitro evolution is much faster than
lead optimization by chemical synthesis and that the
superior library sizes may yield higher-affinity ligands.
A second major advance came with the development
of more general methods for the preparation of
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ing developments was the generation of artificial RNA
enzymes (ribozymes) for tRNA aminoacylation. These
so-called flexizymes [13] have a broad range of substrates
(both tRNAs and amino acids), thus making available a
general group of aminoacylated tRNAs. Recent publica-
tions have demonstrated that the use of one or both of
these technologies for genetic code reprogramming is
beginning to provide access to a diverse group of
peptidomimetics (see Figure 1).
Major recent advances
One of the earliest investigations of ribosomal peptido-
mimetic synthesis used nonsense suppression to
synthesize 16 amino acid peptides incorporating one
unnatural amino acid [14]. Although limited in scope,
this study was promising in that N-methyl-L-phenylala-
nine (MePhe) and L-phenyllactic acid (backbone mod-
ifications) were incorporated in addition to a-amino
acids with unusual side chains. Advances with recon-
stituted cell-free systems allowed the incorporation of
three to five consecutive unnatural amino acids into a
peptide sequence, although the structural scope was
similar to that of the earlier studies [12,15].
Further development of the PURE system for peptide
synthesis allowed simultaneous reassignment of 35 of 61
sense codons to 12 unnatural amino acids that were
previously known to be substrates for aaRSs and
incorporated into proteins by E. coli [16]. Except for
azetidine carboxylic acid, a backbone modification, these
amino acids contain unnatural side chains spanning a
range of physicochemical properties. The alkynyl side
chain of 2-amino-hex-5-ynoic acid is of note, as it can
undergo a copper (I)-catalyzed [3 + 2] cycloaddition
reaction with small-molecule organic azides, leading to
increased post-translational structural diversity [17].
A survey of additional unnatural amino acids showed
that a diverse set of more than 50 amino acids can be
incorporated into peptides by ribosomal translation
[18]. Most of these are side-chain analogs, but also
included are a, a-disubstituted and N-methyl amino
acids (Meaas) and a-hydroxy acids. With this repro-
grammed genetic code, up to 13 different unnatural
substitutions could be incorporated into a single
peptidomimetic. This system potentially can synthesize
unnatural peptide libraries of 10
14 unique members.
Peptide backbone modifications such as Meaas and
cyclization in peptidomimetic structures are useful for
improving protease stability and membrane perme-
ability and introducing conformational constraint [2].
A chemical reductive alkylation approach to over-
coming limitations of scale in chemical aminoacylation
preparation of misacylated tRNAs for ribosomal synth-
esis of Meaa-containing peptides was developed [19].
With this chemistry, the ribosomal synthesis of peptides
containing up to three Meaas was demonstrated [20].
Of the Meaas surveyed, N-methyl leucine (MeLeu),
N-methyl threonine (MeThr), and N-methyl valine
(MeVal) were most efficiently incorporated into
peptides. An alternative approach to a more efficient
preparation of N-methyl aminoacylated tRNA uses
chemically synthesized N-methyl aminoacyl adenosine
monophosphate (AMP) as the substrate for aaRSs [21].
Oligomerization of MePhe assigned to repeat consecu-
tively two, five, or 10 times was demonstrated in an
in vitro display system [22].
Figure 1. Schematic examples of peptidomimetic modifications
achieved by ribosomal synthesis
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Ribosomal synthesis has produced peptidomimetics with considerable
structural diversity. Examples include unnatural side chains, backbone
modifications such as N-methyl amino acids (Meaas) and hydroxy acids, and
peptoids (N-substituted glycine, or rGly). In addition, peptidomimetics
incorporating such features can be cyclized. The macrocyclic rings can be
formed by amino terminus-to-side chain or side chain-to-side chain
cyclization, forming thioether bridges. Bicyclic peptides are synthesized
using two pairs of orthogonally reactive groups to specifically locate the
thioether and triazole bridges. The circled residues in the structures
illustrate that a variety of ring sizes have been shown to be accessible.
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backbone specificity of the E. coli translation machinery
[23]. For the incorporation of alanine (Ala) and
phenylalanine (Phe) analogs into the second position
of a tripeptide, Meaas and hydroxy acids gave good
yields, a, a-disubstituted amino acids incorporated
poorly, and b- and D-amino acids were not detectably
incorporated. Further investigations showed that proper
pairing of Meaas and tRNAs can be important for
efficient expression, but the more bulky N-butyl-Ala
and -Phe were not incorporated [24].
A very recent refinement in the technology for ribosomal
synthesis of Meaa-containing peptides combines the
PURE system, in which both selected amino acids and
aaRSs are withdrawn (wPURE) to vacate certain codons,
with flexizymes for charging unnatural amino acids onto
desired tRNAs [25]. With this system, the N-methyl
analogs of 11 of 19 natural plus four unnatural amino
acids could be incorporated, and the preferences were
somewhat different from those of previous studies.
Peptides containing multiple Meaas were prepared.
In a significant advance, it was demonstrated that cyclic
peptides incorporating Meaas could be synthesized by
assigning an N
a-(a-chloroacetyl) amino acid to the
initiation codon and a cysteine (Cys) to an elongation
codon for a sequence [26]. Under the conditions of the
experiment, the thiol of Cys displaces the a-chloro in an
intramolecular macrocyclization. Examples containing
27-atom rings with three or four Meaas or proline [25]
plus examples with 15-,21-, 36-, and 45-membered rings
with natural amino acids [26] suggest considerable
potential generality for this approach. Furthermore, the
ribosomal synthesis of a library of 160 distinct peptides
having 21-membered macrocycles was achieved. The
macrocycle introduces an additional conformational
constraint into the peptidomimetic, and the ability to
synthesize libraries of such compounds for screening in
biological assays is attractive.
The cyclization in these cases involves side chain-to-
amino terminus ring formation. A side chain-to-side
chain variant has also been developed with the novel
amino acid N
g-(2-chloroacetyl)-a, g-diaminobutyric
acid (Cab) [27]. This amino acid was efficiently
incorporated using the wPURE and flexizyme technolo-
gies, and cyclization with Cys occurred under the
experimental conditions giving examples with 20-, 23-,
26-, and 35-atom rings.
Further extension of this methodology has resulted in the
ribosomal synthesis of bicyclic peptides involving two
pairs of amino acids with orthogonal reactivity [28]. The
pairs of amino acids are Cys and Cab and azidohomo-
alanine (Aha) and propargyl glycine (Pgl), respectively.
As in previous cases, the first macrocyclic ring results
from the formation of the thioether linkage under the
translation reaction conditions. Copper (I) is then used
to catalyze [3 + 2] cycloaddition between the azide and
alkyne side chains to form a triazole as the second bridge
[17]. The preparation of several bicyclic peptidomimetic
structures of different ring sizes serves to illustrate the
versatility of the methodology.
Very recently, ribosomal synthesis of polypeptoids
(poly-N-substituted glycines, or poly-rGlys) [29] and
peptoid-peptide hybrids was reported [30]. A group of
25 rGlys containing a variety of groups was shown to be
incorporated, although bulkiness near the a-amino
group and charged substituents do not work well.
Consecutive rGlys could be incorporated, and cyclization
strategies as previously discussed were also successful for
peptoid-peptide hybrid sequences.
This technology has been extended recently to the
ribosomal synthesis of polyesters [31] and to translation
initiation with D-amino acids [32]. The latter advance
allows for capping the amino terminus of a peptide
sequence with a D-amino acid or acyl-D-amino acid.
Future directions
Recent studies have shown the potential for generating
libraries of peptidomimetic structures of significant
structural diversity using ribosomal synthesis. Testing
of such libraries in high-throughput screens offers the
potential for discovery of leads to novel therapeutic
agents. This approach may be complementary to
chemical synthesis of such structures in terms of ligand
diversity, speed, and cost.
Certain questions remain to be addressed. How broad is
the chemical structural space that can be accessed by
these methods? How useful will such peptidomimetic
structures be as leads to biological tools and therapeutic
agents? Will the purity and integrity of the individual
structures in libraries from ribosomal synthesis be
sufficient? Can promising lead structures be readily
amplified in scale for follow-up studies? Given the
speed at which this field is developing and the creative
approaches being applied, the answers to these questions
should be forthcoming in the near future.
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